Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- GSK to Resume Shipment of Hep B Drug Tenozet
January 18, 2016
- Novartis Partners with Meiji Seika Pharma to Promote COPD Drugs
January 18, 2016
- Ethical Drug Sales Jump 15.2% in November: Crecon Report
January 18, 2016
- MSD Renews Call for Reinstating Govt’s HPV Vaccine Promotion after WHO Statement
January 15, 2016
- Ono Files Etelcalcetide for Secondary Hyperparathyroidism in Japan
January 15, 2016
- Ribomic Inks New Agreement with Otsuka on Midkine Aptamer; Otsuka to Decide on In-Licensing by Year-End
January 15, 2016
- INDEE Medical Obtains Exclusive Distribution Rights in Japan for Autologous Epidermis Transplant Kit from Australian Company
January 15, 2016
- Weber Says Takeda Made “Big Decision” to Pull Plug on Metabolic R&D
January 14, 2016
- Iwaki Top Brass to Return Remunerations over Embezzlement Issue
January 14, 2016
- Mundipharma Looks to Double Japan Sales of OTC Isodine Products in 5 Years
January 14, 2016
- Lenvima Filed for RCC Indication in EU: Eisai
January 13, 2016
- Enbrel Biosimilar Meets Equivalence Criteria in Global PIII: Daiichi Sankyo
January 13, 2016
- Takeda Allies with Canada’s enGene to Develop GI Disease Therapies
January 13, 2016
- Takeda, US Biotech NsGene Team Up on Cell Encapsulation Therapies for Parkinson’s
January 12, 2016
- Otsuka Files Leukemia Drug Ponatinib in Japan
January 12, 2016
- Lilly Japan, Torii Link Up to Copromote Psoriasis Drug Ixekizumab
January 12, 2016
- Astellas, Boehringer Extend Copromotion Pact for Micardis
January 8, 2016
- Sanofi Launches Japan PIII on Vaccine for C. Diff Infection
January 8, 2016
- Nippon Shinyaku Files Japan NDA for PAH Drug Selexipag
January 8, 2016
- Toray Enters Field of Nucleic Acid Medicine through Tie-Up with Bonac
January 8, 2016
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…